Posted by Michael Wonder on 05 Oct 2023
Agomab receives FDA fast track designation for AGMB-129 in fibrostenosing Crohn’s disease
5 October 2023 - Global 12 week Phase 2a trial will evaluate Agomab’s oral GI restricted small molecule ALK5 inhibitor in 36 patients with symptomatic fibrostenosing Crohn’s Disease.
Agomab Therapeutics today announced that it received fast track designation from the US FDA for AGMB-129 for the potential treatment of fibrostenosing Crohn’s disease.
